PCRC_LU002

Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without stereotactic body radiation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving maintenance chemotherapy and stereotactic body radiation therapy together may work better than maintenance chemotherapy alone in treating patients with stage IV non-small cell lung cancer.

Inclusion Criteria:
•Women of childbearing potential and men who are sexually active should be willing and able to use medically acceptable forms of contraception during the trial
•Pathologically proven diagnosis of NSCLC, with metastases (stage IV disease) present prior to registration; this includes patients newly diagnosed with metastatic disease or those initially diagnosed and treated for stage I-III NSCLC who ultimately develop metastases
•Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of normal (ULN) or ≤ 5 × ULN with metastatic liver disease
•Total bilirubin ≤ 1.5 × ULN
•Absolute neutrophil count (ANC) ≥ 500 cells/mm^3
•Creatinine clearance ≥ 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
•Platelets ≥ 50,000 cells/mm^3
•Patients must have received first-line/induction chemotherapy (4 cycles) and achieved stable disease or a partial response

Exclusion Criteria:
•Clinical or radiologic evidence of untreated and/or progressive brain metastases
•Metastatic disease invading the esophagus, stomach, intestines, or mesenteric lymph nodes

Phase II/III
NCT03137771
Cancer
Lung
Dan Zuckerman, M.D.
NRG (NRG Oncology)
Brenda Fisher

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.